The frequency of the BRAF p.Val600Glu variant was 5% to 12% in CRC populations, and the presence of this variant has been found to be associated with poor survival in patients with CRC in several studies in which patients were not treated with anti-EGFR monoclonal antibodies[16], [17], [18], [19], [20], [21], [22], [23]. Here, BRAF is linked to colorectal carcinoma.